03n 0203 ts00002 LEACH

Information about 03n 0203 ts00002 LEACH

Published on November 19, 2007

Author: Me_I

Source: authorstream.com

Content

Slide2:  Contents General considerations for pulmonary drugs Case Study - Proventil-HFA Case Study – QVAR Lung delivery of peptides/proteins Lung delivery of i.v. antibiotics Conclusions General Preclinical Considerations:  General Preclinical Considerations Has the drug been to the site before? Is the local concentration at the new site higher than before? Are the usual metabolic pathways present in the new site? Are there new susceptible cell types (e.g. growth factor issues)? Will new or existing excipients cause problems (e.g. bronchospasm, membrane disruptors)? Will neutralizing or anaphylactic antibodies form? Proventil HFATM (AiromirTM) versus Albuterol CFC:  Proventil HFATM (AiromirTM) versus Albuterol CFC Same drug, different propellant Same amount of drug delivered Same particle size distribution Improved dosing characteristics Slide5:  Proventil HFA Ventolin Proventil-HFA Preclinical Program (registered in 40 countries) :  Proventil-HFA Preclinical Program (registered in 40 countries) Inhalation range-finding study in rats Inhalation range-finding in dogs 28-Day inhalation study in rats 28-Day inhalation study in dogs 90-day inhalation study in rats Inhalation teratology study in rats Slide7:  Clinical Efficacy Study Slide8:  Proventil HFA Preclinical Conclusions No preclinical surprises in two species No PK/ADME clinical surprises No efficacy surprises SO no further preclinical studies necessary QVARTM (HFA-BDP) versus CFC-Beclomethasone (CFC-BDP):  QVARTM (HFA-BDP) versus CFC-Beclomethasone (CFC-BDP) Same drug, different propellant Different amount of drug delivered Different particle size distribution Improved dosing characteristics Human Deposition Pattern:  Human Deposition Pattern QVAR Lung 59% 4% CFC-BDP 8% 1% Exhaled 1.1 microns 3.5 microns QVAR Preclinical Program (registered in 40 countries) :  QVAR Preclinical Program (registered in 40 countries) Inhalation range-finding study in rats Inhalation range-finding in dogs 14-Day inhalation study in rats 14-Day inhalation study in dogs 12-month inhalation study in dogs Inhalation teratology study in rats Pharmacokinetics Model predictions for QVAR:  Pharmacokinetics Model predictions for QVAR Mucocilary clearance Projected Serum Levels Based on Deposition Results:  Projected Serum Levels Based on Deposition Results Beclovent - 100a QVAR - 100a Oral depositionb 95mg 20mg 30mg 6mgc Lung depositionb 5mg 5mg 60mg 60mg Serum Total 25mg 66mg Ratio 1 2.6 : a assumes 100mg of beclomethasone dipropionate is delivered to the patient b assumes an oral bioavailability of 21% and a lung bioavailability of 100% c the formula represents amount deposited serum based on bioavailability Phase 1 Clinical Study Serum Concentrations of BDP After Single Inhaled Doses :  Phase 1 Clinical Study Serum Concentrations of BDP After Single Inhaled Doses Regression analysis of change from baseline in FEV1 as % predicted at week 6:  Regression analysis of change from baseline in FEV1 as % predicted at week 6 26 24 14 16 18 20 22 100 400 800 150 CFC-BDP Qvar Total daily dose (mcg/day) Relative dose ratio 2.6 (95% CI 1.1-11.6) 2.6 Change from baseline in FEV1 as % predicted Long-term asthma control: breakthrough asthma following 2:1 switch:  Long-term asthma control: breakthrough asthma following 2:1 switch HFA-BDP CFC-BDP 0 20 40 60 80 100 Day 1 Wk 4 Wk 8 Mth 4 Mth 6 Mth 8 Mth 10 Mth 12 % patients with no asthma related adverse events Kaplan Meier plot Slide18:  QVAR Preclinical Conclusions No preclinical surprises in two species No PK/ADME clinical surprises No efficacy surprises SO no further preclinical studies necessary Proteins/Peptides :  Proteins/Peptides There are numerous peptides with significant therapeutic activity in every field of medicine BUT, they have serious delivery problems Need to inject Time of action too short Native structures too susceptible to peptidases Slide20:  Local Lung versus Systemic Delivery Rule of thumb is that 2-5% of the i.v. dose reaches the lungs The other 95% adds to unwanted side-effects Insulin Preclinical / Clinical Issues:  Insulin Preclinical / Clinical Issues Insulin is present in virtually every cell Larger local lung concentrations than previously seen Insulin is a growth factor Insulin by any route induces antibody formation Leuprolide :  Leuprolide Analog of LHRH Treatment of endometriosis Treatment of prostate cancer Side effects inhibit its use Leuprolide PulmoSphere™ DPI:  Leuprolide PulmoSphere™ DPI PulmoSphere Particles :  PulmoSphere Particles Hollow Porous Ultra low density Self-Assembling Structures in Water:  Self-Assembling Structures in Water Leuprolide Preclinical / Clinical Issues:  Leuprolide Preclinical / Clinical Issues Larger local lung concentrations than previously seen Antibody question DSPC, DPPC excipients (normal components of lung surfactant) Slide28:  Inhalation versus i.v. of Antibiotic A in rats Antibiotic A inhalation in Dogs:  Antibiotic A inhalation in Dogs 18 20 22 24 26 28 30 0 10 20 30 40 50 Low Dose Mid Dose High Dose ng / mL Plasma Time After Start of Dosing (days) Plasma t1/2 = 28 hours Day 1 Day 14 Day 29 m g/g Lung Antibiotic Concentration Lung Tissue t1/2 = 19 days 4 orders of magnitude delta between lung and plasma Plasma likely to be undetectable at doses targeting MICs in lung Phase-1 Clinical Study of Antibiotic B :  Phase-1 Clinical Study of Antibiotic B 0 0.2 0.4 0.6 0.8 0 4 8 12 16 20 24 Hours (time after end of inhalation) Serum Antibiotic B (ug/ml) PulmoSphere Antibiotic B, 85 mg Nebulized Antibiotic B, 300 mg Antibiotic B in Humans:  Antibiotic B in Humans Minutes to Dose Dry Powder Nebulizer Summary:  Summary A route change to inhalation can offer: Faster onset Higher bioavailability Freedom from injections Less side effects Preclinical requirements should be unique to each new change in route Preclinical programs should stress the exploration of known differences, not unsubstantiated speculation The fear of unknown and/or unreasonable preclinical and clinical requirements keeps many new routes for drug administration economically unattractive (especially for non-blockbuster category drugs) Future Biotech Inhalers:  Future Biotech Inhalers Insulin Growth factors (local & systemic) Interferons Lung surfactants Monoclonal antibodies Receptors Viral vectors

Related presentations


Other presentations created by Me_I

body language
15. 06. 2007
0 views

body language

Pregnant Man Delivers Baby Girl
06. 07. 2008
0 views

Pregnant Man Delivers Baby Girl

Pregnant Man delivers baby girl
04. 07. 2008
0 views

Pregnant Man delivers baby girl

Interview guide
22. 04. 2008
0 views

Interview guide

Price
17. 04. 2008
0 views

Price

valuation models
17. 04. 2008
0 views

valuation models

Stan Mcmillen
14. 04. 2008
0 views

Stan Mcmillen

ABch11
13. 04. 2008
0 views

ABch11

IPStrategy mozambique
10. 04. 2008
0 views

IPStrategy mozambique

magaddinometrans01
09. 04. 2008
0 views

magaddinometrans01

lecture7 07 time cmp
07. 04. 2008
0 views

lecture7 07 time cmp

Easter
09. 07. 2007
0 views

Easter

PHSC1013 Reactions
02. 01. 2008
0 views

PHSC1013 Reactions

Digestive System Disorders
26. 03. 2008
0 views

Digestive System Disorders

ABC on HIV AIDS
16. 06. 2007
0 views

ABC on HIV AIDS

plateau
09. 07. 2007
0 views

plateau

4 YCCC 1500 Competition K1IR
16. 06. 2007
0 views

4 YCCC 1500 Competition K1IR

2DShapes
16. 06. 2007
0 views

2DShapes

Analyzing Political Cartoons 1
15. 06. 2007
0 views

Analyzing Political Cartoons 1

kwanza
09. 07. 2007
0 views

kwanza

7 passions
16. 06. 2007
0 views

7 passions

GreekDrama
09. 07. 2007
0 views

GreekDrama

L9medicine
12. 10. 2007
0 views

L9medicine

Business opportunities 2005
18. 10. 2007
0 views

Business opportunities 2005

Rocio Guirao Diaz
03. 09. 2007
0 views

Rocio Guirao Diaz

Jorge Tellez Fuentes
22. 10. 2007
0 views

Jorge Tellez Fuentes

87 81
22. 10. 2007
0 views

87 81

Active Aging Steps
27. 11. 2007
0 views

Active Aging Steps

Yafei ECG poster final
15. 11. 2007
0 views

Yafei ECG poster final

NACAA Conference FSEP
29. 12. 2007
0 views

NACAA Conference FSEP

chem 101 chapter 6 slides
04. 01. 2008
0 views

chem 101 chapter 6 slides

comp intel
03. 10. 2007
0 views

comp intel

mikelle
28. 12. 2007
0 views

mikelle

Dear God
03. 10. 2007
0 views

Dear God

Team Leader Training 12 11 06
09. 07. 2007
0 views

Team Leader Training 12 11 06

Schneider and Schmitt
09. 07. 2007
0 views

Schneider and Schmitt

paraguay
09. 07. 2007
0 views

paraguay

mowbjan06
09. 07. 2007
0 views

mowbjan06

mlk 2
09. 07. 2007
0 views

mlk 2

Mayan Cosmology
09. 07. 2007
0 views

Mayan Cosmology

GCSE ART D of Dead
09. 07. 2007
0 views

GCSE ART D of Dead

Enter the 2007 Art Comp1
09. 07. 2007
0 views

Enter the 2007 Art Comp1

cases
24. 02. 2008
0 views

cases

a032405
09. 10. 2007
0 views

a032405

sfa ch2
01. 01. 2008
0 views

sfa ch2

6 12USAITAsecondpanel
22. 10. 2007
0 views

6 12USAITAsecondpanel

Gatekeepers 6
11. 12. 2007
0 views

Gatekeepers 6

EU New Member States Brno NA
18. 03. 2008
0 views

EU New Member States Brno NA

Rym Kefi
05. 01. 2008
0 views

Rym Kefi

Chinese Dynasties
25. 03. 2008
0 views

Chinese Dynasties

2 4 Adams Hallam
07. 10. 2007
0 views

2 4 Adams Hallam

Wings of the Centennial
09. 07. 2007
0 views

Wings of the Centennial

Creating a User Group 2005
30. 03. 2008
0 views

Creating a User Group 2005

Observation
09. 07. 2007
0 views

Observation

usingmypyramidadult
04. 03. 2008
0 views

usingmypyramidadult

Stefan Stanciugelu
15. 10. 2007
0 views

Stefan Stanciugelu

carreira
19. 06. 2007
0 views

carreira

Capitalization Part 2
19. 06. 2007
0 views

Capitalization Part 2

Caceres 2007
19. 06. 2007
0 views

Caceres 2007

CHETEMPOFA
18. 06. 2007
0 views

CHETEMPOFA

cervantes
18. 06. 2007
0 views

cervantes

CEIS 23 06
18. 06. 2007
0 views

CEIS 23 06

cartoon classics
18. 06. 2007
0 views

cartoon classics

cardiac2
19. 06. 2007
0 views

cardiac2

hphennalect
09. 07. 2007
0 views

hphennalect

Current Presentation March06
18. 06. 2007
0 views

Current Presentation March06

cul 18
18. 06. 2007
0 views

cul 18

competitive rviews
18. 06. 2007
0 views

competitive rviews

company wbc
18. 06. 2007
0 views

company wbc

City Guide Mobile web en
18. 06. 2007
0 views

City Guide Mobile web en

MICROIII Aula11
14. 11. 2007
0 views

MICROIII Aula11

comunicado2
22. 10. 2007
0 views

comunicado2

Camilla Schreiner UiO
19. 06. 2007
0 views

Camilla Schreiner UiO

verb som laanord
27. 09. 2007
0 views

verb som laanord

LCWS05 gao 1
12. 10. 2007
0 views

LCWS05 gao 1

ambiguity
16. 06. 2007
0 views

ambiguity

all about burgers 1
16. 06. 2007
0 views

all about burgers 1

AGME 1
16. 06. 2007
0 views

AGME 1

Advanced ADO
16. 06. 2007
0 views

Advanced ADO

adolposter winkles
16. 06. 2007
0 views

adolposter winkles

AbrahamseOverviewAM
16. 06. 2007
0 views

AbrahamseOverviewAM

31 Presentation
16. 06. 2007
0 views

31 Presentation

303lec09
16. 06. 2007
0 views

303lec09

04 06 training
15. 06. 2007
0 views

04 06 training

Brian PM FINAL
15. 06. 2007
0 views

Brian PM FINAL

Berkeley ISSC Feb 07
15. 06. 2007
0 views

Berkeley ISSC Feb 07

Autism 06 BU handout
15. 06. 2007
0 views

Autism 06 BU handout

Attraction
15. 06. 2007
0 views

Attraction

Asali
15. 06. 2007
0 views

Asali

April Showers
15. 06. 2007
0 views

April Showers

APA San Diego
15. 06. 2007
0 views

APA San Diego

ap05blogs
15. 06. 2007
0 views

ap05blogs

anastasatos
15. 06. 2007
0 views

anastasatos

Analyzing Political Cartoons
15. 06. 2007
0 views

Analyzing Political Cartoons

analyzing cartoons incent asia
15. 06. 2007
0 views

analyzing cartoons incent asia

africanamericanhumor
16. 06. 2007
0 views

africanamericanhumor

americanpoplanguage
15. 06. 2007
0 views

americanpoplanguage

mainmenu2007changes jml
06. 03. 2008
0 views

mainmenu2007changes jml

StephenAbram RecreatingServices3
10. 03. 2008
0 views

StephenAbram RecreatingServices3

Joanna Krupa
03. 09. 2007
0 views

Joanna Krupa

HowtheWestWasWon
19. 02. 2008
0 views

HowtheWestWasWon

accidental humor
16. 06. 2007
0 views

accidental humor

keyes
03. 01. 2008
0 views

keyes

VolkswagenCoaching
16. 11. 2007
0 views

VolkswagenCoaching

07 kauai1
26. 02. 2008
0 views

07 kauai1

Urban Waters and Ports html
30. 12. 2007
0 views

Urban Waters and Ports html

awakening
15. 06. 2007
0 views

awakening

RR11 NIA Hodes
03. 01. 2008
0 views

RR11 NIA Hodes

AAAR diesel1
29. 02. 2008
0 views

AAAR diesel1

RSS AnnualMtg3
29. 09. 2007
0 views

RSS AnnualMtg3

USTC
29. 11. 2007
0 views

USTC

ESS Adv Plan Present 4 18
09. 07. 2007
0 views

ESS Adv Plan Present 4 18

CMR0101
18. 06. 2007
0 views

CMR0101